Agile评分在MASLD和ALD中的外部验证及其在临床算法中的效用
本研究纳入4243例患者(MASLD 912例、ALD 386例、CHB 597例、CHC 2348例),在6个月内完成肝脏硬度测量、肝活检和实验室检查,验证Agile 3+和Agile 4评分对进展期纤维化(F≥3)和肝硬化的诊断准确性。结果显示Agile 3+/4在MASLD和ALD中与LSM诊断准确性相当,但在CHB/C中表现较差;作为FIB-4>1.3后的第二步策略,Agile 3+较LSM正确分类率更高且不确定结果更少。
要点
- Agile 3+与LSM诊断MASLD和ALD的F≥3准确性相似(MASLD AUC 0.86 vs 0.86,ALD 0.92 vs 0.94)。
- FIB-4>1.3后序贯使用Agile 3+较LSM正确分类率更高(MASLD 75% vs 71%,ALD 76% vs 72%),不确定结果更少。
- LSM与Agile 3+/4联合阳性一致可提高进展期纤维化/肝硬化诊断的特异性。
核心结论
- Agile 3+和Agile 4在MASLD和ALD中与LSM诊断准确性相当,但不确定结果更少。
- FIB-4序贯Agile 3+/4或Agile 3+/4与LSM联合使用可进一步优化F≥3诊断。
研究设计与样本
- 纳入4243例患者(MASLD 912例、ALD 386例、CHB 597例、CHC 2348例),均有6个月内LSM、肝活检和实验室检查。
- 计算FIB-4、Agile 3+和Agile 4评分,并在临床算法中与FIB-4和LSM联合评估。
主要发现
- F≥3:Agile 3+与LSM诊断准确性在MASLD相似(AUC 0.86 vs 0.86,p=0.831),在ALD相似(0.92 vs 0.94,p=0.123)。
- 肝硬化:Agile 4与LSM在MASLD相似(AUC 0.89 vs 0.90,p=0.412),在ALD相似(0.94 vs 0.95,p=0.513)。
- Agile 3+/4在CHB/C中表现劣于LSM。
- 采用预设90%敏感度/特异度双阈值,MASLD正确分类率Agile 3+ vs LSM双cut-off为66% vs 61%,ALD为71% vs 67%。
- FIB-4>1.3后序贯Agile 3+或LSM,正确分类率Agile 3+更高:MASLD 75% vs 71%,ALD 76% vs 72%,且不确定结果更少。
关键数值与推荐
- Agile 3+用于F≥3诊断,Agile 4用于肝硬化(F4)诊断。
- 双阈值策略采用预设90%敏感度/特异度。
- 序贯策略:FIB-4>1.3后接Agile 3+或LSM作为第二步。
临床怎么用
- 在MASLD和ALD中,Agile 3+/4可作为LSM的替代用于诊断进展期纤维化/肝硬化。
- 可采用FIB-4序贯Agile 3+/4或Agile 3+/4与LSM联合的策略优化F≥3诊断。
- Agile评分在慢性病毒性肝炎中表现不如LSM。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Agile scores, including liver stiffness measurements (LSM) and routine clinical/laboratory biomarkers, have been developed for advanced fibrosis (F≥3) and cirrhosis (F4), respectively, in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). We independently validated the diagnostic accuracy of these scores in MASLD, alcohol-related liver disease (ALD) and chronic hepatitis B or C (CHB/C) and assessed them in clinical algorithms with FIB-4 and LSM. METHODS: We included 4,243 patients (MASLD: 912, ALD: 386, CHB: 597, CHC: 2,348) with LSM, liver biopsy and laboratory tests within 6 months. FIB-4, Agile 3+ and Agile 4 scores were calculated. RESULTS: For F≥3, the diagnostic accuracy of Agile 3+ and LSM were similar in MASLD (AUC: 0.86 vs. 0.86, p = 0.831) and ALD (0.92 vs. 0.94, p = 0.123). For cirrhosis, Agile 4 was similar to LSM in MASLD (0.89 vs. 0.90, p = 0.412) and ALD (0.94 vs. 0.95, p = 0.513). Agile 3+/4 performed worse than LSM in CHB/C. Using predefined dual thresholds of 90% sensitivity/specificity, correct classification rates in MASLD were 66% vs. 61% using Agile 3+ vs. LS dual cut-offs and 71% vs. 67% in ALD, respectively. When using Agile 3+ or LSM as a second step after FIB-4 >1.3, correct classification rates were higher with Agile 3+ than LSM, both for MASLD (75% vs. 71%) and ALD (76% vs. 72%), with fewer indeterminate results. Positive agreement of LSM and Agile 3+/4 significantly increased the specificity of a diagnosis of advanced fibrosis/cirrhosis. CONCLUSION: Agile 3+ and Agile 4 have equal diagnostic accuracy with LSM in both MASLD and ALD but result in fewer indeterminate results. Sequential use of FIB-4 and Agile 3+/4 or concurrent Agile 3+/4 and LSM can be used to further optimize F≥3 diagnosis. IMPACT AND IMPLICATIONS: As of today, it is accepted that there will be no single non-invasive test or an isolated cut-off for identifying patients with advanced chronic liver disease. Here, we confirmed that Agile 3+ and Agile 4 scores are useful alternatives to simple liver stiffness measurement in diagnosing advanced fibrosis/cirrhosis in steatotic liver disease, but they do not perform as well in chronic viral hepatitis. Agile scores can help optimize the diagnosis of advanced fibrosis/cirrhosis in a dual cut-off strategy by reducing the number of indeterminate results either alone or in a sequential strategy after FIB-4. The combination of Agile scores and liver stiffness measurement can further increase our confidence in a positive diagnosis of advanced fibrosis/cirrhosis. These novel combination strategies can be useful tools to predict the likelihood of advanced stages of liver disease with the highest possible accuracy in a secondary/tertiary healthcare setting.
引用
- Papatheodoridi M, De Ledinghen V, Lupsor-Platon M, et al. Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms. J Hepatol. 2024. PMID: 38789011. doi:10.1016/j.jhep.2024.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。